Cell-Specific Actions of IL-1 / IL-1R1 Signaling Following Traumatic Brain Injury
脑外伤后 IL-1/IL-1R1 信号传导的细胞特异性作用
基本信息
- 批准号:10307112
- 负责人:
- 金额:$ 32.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-12-15 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAttenuatedBlood VesselsBrainCellsCentral Nervous System DiseasesChronicClinicalClosed head injuriesDataDevelopmentDiseaseElectrophysiology (science)Endothelial CellsEndotheliumExtravasationFDA approvedFailureFunctional disorderGenerationsGeneticGoalsImmunomodulatorsImmunosuppressive AgentsImpaired cognitionImpairmentInflammationInflammatoryInjuryInterleukin SuppressionInterleukin-1Interleukin-1 ReceptorsKnockout MiceKnowledgeLeadLearningLoxP-flanked alleleMemoryModelingMolecularMusNatureNerve DegenerationNeurodegenerative DisordersNeuronal InjuryOutcomePathologicPathway interactionsPatient-Focused OutcomesPharmaceutical PreparationsPublic HealthRadialReceptor SignalingRegulationResidual stateRisk FactorsRoleSeveritiesSignal TransductionSynapsesSynaptic plasticityTestingTimeTraumatic Brain InjuryVascular DiseasesVascular remodelingVertebral columnarmblood-brain barrier permeabilizationbrain endothelial cellcell typecentral nervous system injurycerebral atrophydensityimprovedmild traumatic brain injurymouse modelneuroinflammationneuroprotectionnovelresponserestorationsevere injurytargeted treatmentwater maze
项目摘要
ABSTRACT
Management of neuroinflammation is a promising target for improving patient outcomes following a
traumatic brain injury (TBI), and substantial evidence suggests therapies targeting the interleukin-1 receptor
(IL-1R1) pathway may control neuroinflammation. Despite the promise, there have been limited attempts to
move anti-interleukin-1 (IL-1) drugs forward for TBI neuroprotection. We hold that a critical reason for the lack
of progress on this promising target is the incomplete understanding of the mechanistic underpinnings of IL-1
signaling after a TBI. It is well-recognized that the clinical picture of TBI is a spectrum of different primary injury
mechanisms and injury severities, and that it is necessary to understand the secondary injury mechanism as
they relate to the primary injury. Over 75% of TBIs are classified as mild. While not all TBIs lead to
neurodegeneration, a mild TBI can result in progressive brain atrophy and persistent cognitive dysfunction, and
is a known risk factor for the development of Alzheimer’s disease and related dementias. The current
knowledge of IL-1 / IL-1R1 signaling after a TBI is almost exclusively following a moderate-to-severe injury.
Using our novel genetic mouse models that allow for cell-type regulation of IL-1R1 signaling, and our model of
mild TBI caused by a closed head injury (CHI) we will address this fundamental gap in our knowledge by
testing the role of IL-1R1 following a mild TBI, and for the first time, define a cellular mechanism for the
pathological effects of IL-1R1 following a mild TBI. Importantly our exciting preliminary data has uncovered a
critical role for the brain endothelium in regulating neuroinflammation, which is dependent on IL-1R1. Our
preliminary results have led us to propose the overall hypothesis: Secondary neuronal injury following a
mild TBI is driven by neuroinflammation and vascular dysfunction, which can be reduced through
suppression of IL-1R1. The actions of IL-1R1 following a mild TBI will require the involvement of
endothelial cells. We will test our hypothesis in the following aims:
Aim 1: Assess the role of endothelial IL-1R1 signaling in the neuroinflammatory feedforward loop.
Aim 2: Define the role of endothelial IL-1R1 signaling in the vascular response to a CHI.
Aim 3: Delineate the role of endothelial IL-1R1 signaling on synaptic plasticity and spatial learning and
memory following a CHI.
Successful completion of these studies will increase our understanding of the role of IL-1R1 after a mild
TBI, and define the role of the brain endothelium in the neuroinflammatory response to a mild TBI. Our results
will fill a critical knowledge gap concerning how best to target neuroinflammation to achieve neuroprotection
after a mild TBI, and potential for other disease associated with neuroinflammation (i.e., Alzheimer’s disease).
摘要
神经炎症的管理是一个有希望的目标,以改善患者的结果后,
创伤性脑损伤(TBI),大量证据表明治疗靶向白细胞介素-1受体
(IL-1 R1)通路可能控制神经炎症。尽管有这样的承诺,
将抗白细胞介素-1(IL-1)药物用于TBI神经保护。我们认为,一个关键的原因,缺乏
在这个有希望的目标上取得进展的原因是对IL-1的机制基础的不完全理解
TBI后的信号众所周知,TBI的临床表现是一系列不同的原发性损伤
机制和损伤严重程度,并且有必要了解继发性损伤机制,
它们与原发性损伤有关。超过75%的TBI被归类为轻度。虽然不是所有的TBI都会导致
轻度TBI可导致进行性脑萎缩和持续性认知功能障碍,
是阿尔茨海默病和相关痴呆症的一个已知的危险因素。当前
TBI后IL-1 / IL-1 R1信号传导的知识几乎完全是在中度至重度损伤后。
使用我们的新的遗传小鼠模型,允许IL-1 R1信号传导的细胞类型调节,以及我们的模型,
闭合性颅脑损伤(CHI)引起的轻度TBI,我们将通过以下方式解决我们知识中的这一根本性差距:
测试IL-1 R1在轻度TBI后的作用,并首次定义了
IL-1 R1在轻度TBI后的病理作用。重要的是,我们令人兴奋的初步数据揭示了一个
脑内皮在调节神经炎症中的关键作用,这依赖于IL-1 R1。我们
初步结果使我们提出了一个总体假设:继发性神经元损伤后,
轻度TBI是由神经炎症和血管功能障碍引起的,可以通过
抑制IL-1 R1。IL-1 R1在轻度TBI后的作用将需要以下参与:
内皮细胞我们将在以下目标中检验我们的假设:
目的1:评估内皮细胞IL-1 R1信号传导在神经炎症前馈回路中的作用。
目的2:确定内皮细胞IL-1 R1信号在血管对CHI反应中的作用。
目的3:阐明内皮细胞IL-1 R1信号在突触可塑性和空间学习中的作用,
记忆跟随着CHI。
这些研究的成功完成将增加我们对IL-1 R1在轻度脑缺血后作用的理解。
TBI,并定义脑内皮细胞在轻度TBI的神经炎症反应中的作用。我们的结果
将填补关于如何最好地靶向神经炎症以实现神经保护的关键知识空白
在轻度TBI后,以及与神经炎症相关的其他疾病的可能性(即,阿尔茨海默病)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ADAM D BACHSTETTER其他文献
ADAM D BACHSTETTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ADAM D BACHSTETTER', 18)}}的其他基金
Drug repurposing for Alzheimer’s disease-related inflammation caused by a TBI
药物再利用,治疗 TBI 引起的阿尔茨海默病相关炎症
- 批准号:
10590132 - 财政年份:2023
- 资助金额:
$ 32.72万 - 项目类别:
Neuronal IL-1R1 Signaling in Mild Closed Head Injury
轻度闭合性头部损伤中的神经元 IL-1R1 信号转导
- 批准号:
10518172 - 财政年份:2022
- 资助金额:
$ 32.72万 - 项目类别:
Neuronal IL-1R1 Signaling in Mild Closed Head Injury
轻度闭合性头部损伤中的神经元 IL-1R1 信号转导
- 批准号:
10656547 - 财政年份:2022
- 资助金额:
$ 32.72万 - 项目类别:
Translational Approaches to Mitigate Enhanced Alzheimer’s Disease Risk Following a Mild TBI
减轻轻度 TBI 后阿尔茨海默病风险增加的转化方法
- 批准号:
10090757 - 财政年份:2021
- 资助金额:
$ 32.72万 - 项目类别:
Administrative Supplement to Sleep Fragmentation and Alzheimer's Disease
睡眠碎片化和阿尔茨海默病的行政补充
- 批准号:
10555721 - 财政年份:2020
- 资助金额:
$ 32.72万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 32.72万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 32.72万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 32.72万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 32.72万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 32.72万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 32.72万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 32.72万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 32.72万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 32.72万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 32.72万 - 项目类别:
Research Grant